Anti-Migraine Retargeting

A small Life Sciences organization had an established product in the Oral CGRP market focused on acute treatment of migraines.

Fifteen months post launch, the brand received an additional indication for the preventative treatment of episodic migraines.

Ahead of launch for the acute indication, Propensity4 leveraged market research to understand the attitudes of the HCP population.
We then correlated attitudes and behaviors demonstrated in claims data to develop a scoring mechanism across the HCP universe and developed targeting for 585 reps to accelerate adoption in acute patients.
Ahead of the preventative launch, Propensity4 applied our scoring mechanism to identify previously non-targeted HCPs with preventative patients.
At launch, Propensity4 issued new targeting for the existing and a new preventative indication sales team.

Propensity4 was able to deliver a final targeting scheme in 8 weeks, marrying primary and secondary data to create an informed targeting approach.

The brand was able to deliver 4x the forecast across both indications in a highly genericized market.

Learn more about our work.

For more case studies and insights from Propensity4, click below.

Jump to a slide with the slide dots.

We’re thrilled to announce that Isabelle Amick has joined Propensity4 as our new Senior Director of Data Science!

End-to-end US launch support for EU client’s dry eye device—from KAM team and CRM setup to data analytics, targeting, and incentive strategy.

This blog explores how “bottom-up” forecasting, particularly Most Probable Forecasting (MPF), enhances pharmaceutical brand planning.

Personalized patient engagement boosted therapy adherence with AI-driven insights, risk scoring, and tailored support recommendations.

Accelerating rare disease diagnosis through data-driven patient finding and predictive modeling to connect patients with the right HCPs faster.